The Committee reviews and evaluates data concerning the safety and effectiveness of marketed and investigational human drug products for use in the treatment of arthritis, rheumatism, and related diseases, and makes appropriate recommendations to the Commissioner of Food and Drugs.

April 24-25, 2018 Meeting of the Arthritis Advisory Committee

• April 24-25, 2018: Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee Meeting Announcement
• Waiver for Conflicts of Interest for the April 24-25, 2018 Joint Meeting of the Arthritis Advisory Committee (AAC) and the Drug Safety and Risk Management Advisory Committee (DSaRM)
• Arthritis Advisory Committee Roster for the April 24-25, 2018 Joint Meeting of the Arthritis Advisory Committee (AAC) and the Drug Safety and Risk Management Advisory Committee (DSaRM)
• Drug Safety and Risk Management Advisory Committee Roster for the April 24-25, 2018 Joint Meeting of the Arthritis Advisory Committee (AAC) and the Drug Safety and Risk Management Advisory Committee (DSaRM)
• Webcast Information for the April 24-25, 2018 Joint Meeting of the Arthritis Advisory Committee (AAC) and Drug Safety and Risk Management Advisory Committee (DSaRM)
• Briefing Information for the April 24-25, 2018 Joint Meeting of the Arthritis Advisory Committee (AAC) and Drug Safety and Risk Management Advisory Committee (DSaRM)
• Final Agenda for the April 24-25, 2018 Joint Meeting of the Arthritis Advisory Committee (AAC) and the Drug Safety and Risk Management Advisory Committee (DSaRM)
• Final Questions for the April 24-25, 2018 Joint Meeting of the Arthritis Advisory Committee (AAC) and the Drug Safety and Risk Management Advisory Committee (DSaRM)
• Final Meeting Roster for the April 24-25, 2018 Joint Meeting of the Arthritis Advisory Committee (AAC) and the Drug Safety and Risk Management Advisory Committee (DSaRM)
• Slides for the April 24-25, 2018 Joint Meeting of the Arthritis Advisory Committee (AAC) and Drug Safety and Risk Management Advisory Committee (DSaRM)
• Minutes for the April 24-25, 2018 Joint Meeting of the Arthritis Advisory Committee (AAC) and Drug Safety and Risk Management Advisory Committee (DSaRM)
• Transcript for the April 24, 2018 Joint Meeting of the Arthritis Advisory Committee (AAC) and Drug Safety and Risk Management Advisory Committee (DSaRM)
• Transcript for the April 25, 2018 Joint Meeting of the Arthritis Advisory Committee (AAC) and Drug Safety and Risk Management Advisory Committee (DSaRM)

April 23, 2018 Meeting of the Arthritis Advisory Committee

• April 23, 2018: Arthritis Advisory Committee Meeting Announcement
• Committee Roster for the April 23, 2018 Meeting of the Arthritis Advisory Committee (AAC)
• Webcast Information for the April 23, 2018 Meeting of the Arthritis Advisory Committee (AAC)
• Briefing Information for the April 23, 2018 Meeting of the Arthritis Advisory Committee (AAC)
• Final Agenda for the April 23, 2018 Meeting of the Arthritis Advisory Committee (AAC)
• Final Questions for the April 23, 2018 Meeting of the Arthritis Advisory Committee (AAC)
• Final Meeting Roster for the April 23, 2018 Meeting of the Arthritis Advisory Committee (AAC)
• Slides for the April 23, 2018 Meeting of the Arthritis Advisory Committee (AAC)
• Minutes for the April 23, 2018 Meeting of the Arthritis Advisory Committee (AAC)
• Transcript for the April 23, 2018 Meeting of the Arthritis Advisory Committee (AAC)